Literature DB >> 8098985

Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma.

F G Barr1, N Galili, J Holick, J A Biegel, G Rovera, B S Emanuel.   

Abstract

We have determined that PAX3 (found previously to be mutated in Waardenburg syndrome) is the chromosome 2 locus rearranged by the t(2;13)(q35;q14) translocation of the paediatric solid tumour alveolar rhabdomyosarcoma. The rearrangement breakpoints occur within an intron downstream of the paired box and homeodomain-encoding regions. Upstream PAX3 sequences hybridize to a novel transcript in t(2;13)-containing lines. Cloning and characterization of this novel transcript indicate that the translocation juxtaposes the PAX3 DNA binding elements with chromosome 13 sequences, suggesting formation of a hybrid transcription factor. Therefore, PAX3 gene alterations are associated with two completely unrelated human diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098985     DOI: 10.1038/ng0293-113

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  148 in total

Review 1.  Diagnosis and classification of the small round-cell tumors of childhood.

Authors:  S L Cohn
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

2.  Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis.

Authors:  Lydie Pani; Melissa Horal; Mary R Loeken
Journal:  Genes Dev       Date:  2002-03-15       Impact factor: 11.361

3.  Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.

Authors:  R J Davis; F G Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.

Authors:  Joseph G Pressey; Marilyn C Haas; Christine S Pressey; Virginia M Kelly; Jacqueline N Parker; G Yancey Gillespie; Gregory K Friedman
Journal:  Pediatr Blood Cancer       Date:  2012-03-09       Impact factor: 3.167

5.  MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.

Authors:  Chi Wai So; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

Review 6.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

7.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

8.  Zebrafish models of rhabdomyosarcoma.

Authors:  Eleanor Y Chen; David M Langenau
Journal:  Methods Cell Biol       Date:  2011       Impact factor: 1.441

9.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.

Authors:  Charles Keller; Benjamin R Arenkiel; Cheryl M Coffin; Nabeel El-Bardeesy; Ronald A DePinho; Mario R Capecchi
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

10.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.